Clinical Trials · NCT05046132
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Enrollment
- 77
- Start date
- Aug 2021
- Locations
- 1 site, United States
- Primary endpoint
- Setmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10